Please use this identifier to cite or link to this item:
|Title:||Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years : analysis from Phase Three of the ISAAC programme|
Clayton, Tadd O.
Von Mutius, Erika
Lai, Christopher K. W.
Stewart, Alistair W.
|Authors:||ISAAC Phase Three Study Group|
|Keywords:||Asthma -- Case studies|
Allergy in children
|Citation:||Beasley, R., Clayton, T., Crane, J., Von Mutius, E., Lai, C. K., Montefort, S.,...ISAAC Phase Three Study Group. (2008). Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme. The Lancet, 372(9643), 1039-1048.|
|Abstract:||Background: Exposure to paracetamol during intrauterine life, childhood, and adult life may increase the risk of developing asthma. We studied 6–7-year-old children from Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) programme to investigate the association between paracetamol consumption and asthma. Methods: As part of Phase Three of ISAAC, parents or guardians of children aged 6–7 years completed written questionnaires about symptoms of asthma, rhinoconjunctivitis, and eczema, and several risk factors, including the use of paracetamol for fever in the child’s fi rst year of life and the frequency of paracetamol use in the past 12 months. The primary outcome variable was the odds ratio (OR) of asthma symptoms in these children associated with the use of paracetamol for fever in the fi rst year of life, as calculated by logistic regression. Findings: 205 487 children aged 6–7 years from 73 centres in 31 countries were included in the analysis. In the multivariate analyses, use of paracetamol for fever in the first year of life was associated with an increased risk of asthma symptoms when aged 6–7 years (OR 1•46 [95% CI 1•36–1•56]). Current use of paracetamol was associated with a dose-dependent increased risk of asthma symptoms (1•61 [1•46–1•77] and 3•23 [2•91–3•60] for medium and high use vs no use, respectively). Use of paracetamol was similarly associated with the risk of severe asthma symptoms, with population-attributable risks between 22% and 38%. Paracetamol use, both in the first year of life and in children aged 6–7 years, was also associated with an increased risk of symptoms of rhinoconjunctivitis and eczema. Interpretation: Use of paracetamol in the first year of life and in later childhood, is associated with risk of asthma, rhinoconjunctivitis, and eczema at age 6 to 7 years. We suggest that exposure to paracetamol might be a risk factor for the development of asthma in childhood.|
|Description:||We thank the children and parents who participated in ISAAC Phase Three, and the school staff for their coordination and assistance. The authors also acknowledge and thank the many funding bodies throughout the world that supported the individual ISAAC centres, collaborators, and their meetings. Currently, the main source of funding for the ISAAC International Data Centre (IIDC) is The BUPA Foundation. Many funding bodies in New Zealand have contributed to support the IIDC during the periods of fi eldwork and data compilation: the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke’s Bay Medical Research Foundation, the Waikato Medical Research Foundation, GlaxoWellcome New Zealand, the New Zealand Lottery Board, and Astra Zeneca New Zealand. GlaxoWellcome International Medical Aff airs supported the regional coordination for Phase Three and the IIDC.|
|Appears in Collections:||Scholarly Works - FacM&SMed|
Files in This Item:
|Association between paracetamol use in infancy and risk of asthma__.pdf|
|192.83 kB||Adobe PDF||View/Open Request a copy|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.